RecruitingRecurrent Hepatocellular Carcinoma
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
Sponsor: Sun Yat-sen University
You may qualify if…
- ✓ 1. Diagnosed as recurrent hepatocellular carcinoma after curative treatment;
- ✓ 2. The criteria for resectability is met;
- ✓ 3. Has at least one evaluable lesion according to the RECIST 1.1 standard and has not received local treatment;
- ✓ 4. Eastern Cooperative Oncology Group score 0-1, Child-pugh score 5-7;
- ✓ 5. Agree to biopsy and blood sample collection;
- ✓ 6. Adequate organ and marrow function.
You may not qualify if…
- ✕ 1. Previously received any transarterial chemoembolization and immune therapy and other local or systemic liver cancer treatments, except for curative ablation;
- ✕ 2. Extrahepatic metastasis;
- ✕ 3. History of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding;
- ✕ 4. History of autoimmune disease or need to take immunosuppressant drugs for a long time;
- ✕ 5. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
- ✕ 6. Abnormal organ function
Source: ClinicalTrials.gov · NCT04615143 · last updated 2025-01-09